Patents by Inventor Kanato YAMAGATA

Kanato YAMAGATA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200360363
    Abstract: A novel therapeutic agent effective for the treatment of intellectual disability or autism is disclosed. The therapeutic agent for intellectual disability or autism contains, as an active component(s), at least one selected from the group consisting of tipifarnib and lonafarnib. Examples of the intellectual disability include memory impairment. Examples of the memory impairment include memory impairment caused by abnormality of the Tsc1 gene and/or Tsc2 gene, and epilepsy-induced memory impairment. Also provided is a method of treating intellectual disability or autism, comprising administering an effective amount of at least one selected from the group consisting of tipifarnib and lonafarnib to a patient with intellectual disability or autism.
    Type: Application
    Filed: November 7, 2018
    Publication date: November 19, 2020
    Applicant: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
    Inventors: Kanato YAMAGATA, Tadayuki SHIMADA, Hiroko SUGIURA, Shin YASUDA